Stock comparison
Aurinia Pharmaceuticals
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AUPH
Aurinia Pharmaceuticals
Market cap
$1.96B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AUPH | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 56C | 75B | IDXX |
| Benjamin Graham | 54D | 80A | IDXX |
| Philip Fisher | 59C | 75B | IDXX |
| Peter Lynch | 81A | 71B | AUPH |
| Joel Greenblatt | 63C | 83C | IDXX |
| Charlie Munger | 49D | 87A | IDXX |
| Terry Smith | 48D | 84A | IDXX |
Side-by-side metrics
| Metric | AUPH | IDXX |
|---|---|---|
| Market cap | $1.96B | $44.12B |
| P/E (TTM) | 6.9x | 39.0x |
| EV/EBIT | 19.4x | 31.6x |
| ROIC (TTM) | 18.99% | 40.66% |
| Gross margin | 89.74% | 62.05% |
| Net margin | 99.97% | 24.63% |
| Revenue CAGR 5y | 57.84% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AUPH leads on
- Revenue CAGR 5y57.84%vs 7.56%+87%
- Debt / Equity0.1xvs 0.7x+83%
- P/E (TTM)6.9xvs 39.0x+82%
- Net margin99.97%vs 24.63%+75%
IDXX leads on
- Market cap$44.12Bvs $1.96B+96%
- ROIC (TTM)40.66%vs 18.99%+53%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.